The Supreme Court and the “Laws of Nature”
This article was originally published in RPM Report
Shortly before taking up the health care reform law, the Supreme Court weighed in on the intellectual property framework for personalized medicine. Here is an excerpt from the court’s March 20 opinion in Mayo v. Prometheus, in which the court ruled that Prometheus’ patents on a pharmacogenomic technique invalid.
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.